Table 2

Oncological outcome measures

VariablesIntervention groupControl groupP value
n=21%n=19%
Oncological
NAC regimen*FLOT1155842.10.527
Other9451157.9
NAC completed*Yes15751684.21.000
Dose reduced420315.8
Delayed1500
Histopathological:
Mandard Tumour Regression Grade
Best score per patient129.515.25
2523.800.0
3838.1631.6
4314.31157.9
529.515.25
 Combined*1–31575736.80.025
4–5523.81263.2
 Combined*1–273515.30.044
3–513651894.7
Lymph Node Regression Score
 Best score per patient1–34502250.608
4–5450675
Neg LN45
 Combined1–2450112.50.282
3–5450787.5
 Worst score per patient1–2450000.077
3–54508100
Downstaging (cTNM-ypTNM)
 T-downstagingYes1466.7631.60.056
No733.31368.4
 N-downstagingYes1257.1947.40.752
No942.91052.6
 Combined downstagingYes942.9315.80.089
No/mixed1257.11684.2
 Surgical resection margin statusR01471.41473.41.000
R1628.6526.3
  • *Denotes patients with available MTRG (n=20); p values for categorical values Fisher’s exact test unless stated otherwise.

  • cTNM, Clinical TNM stage; FLOT, fluorouracil plus leucovorin, oxaliplatin and docetaxel; LNs, lymph nodes; NAC, neo-adjuvant chemotherapy; ypTNM, pathological TNM stage.